Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
We report a rare case of 74-year-old female of primary hyperparathyroidism caused by parathyroid carcinoma (PC) and coexisting multiple parathyroid adenomas. She was referred to our hospital for primary hyperparathyroidism and a suspected thyroid tumor. She had no family history of malignant tumor. Computed tomography (CT) and ultrasonography of the neck revealed some masses posterior to both thyroid lobes. Those masses were believed to be parathyroid lesions. However, another mass located posterior to the right upper thyroid lobe seemed to be heterogeneous, which indicated a malignant thyroid tumor as well as parathyroid ...
We describe a unique, complex case of a man resulted affected by both APS-2 and MEN-2a. The patient developed Hashimoto's thyroiditis, diabetes mellitus type 1 and AAD, despite testing negative for adrenal cortex autoantibodies (ACA) and steroid 21-hydroxylase autoantibodies (21-OHAb). Moreover, he had also a family history for MEN-2a and he first developed medullay thyroid cancer, then bilateral pheochromocytoma on the adrenal substrate of an AAD. On adrenal histology we found complete bilateral cortical atrophy in the presence of a lymphocytic infiltration and fibrosis, confirming an ACA and 21-OHAb-negative AAD. This da...
CONCLUSIONS: The ATA risk stratification system is a reliable predictor of short-term outcomes in patients with DTC in real-world clinical settings characterized by center heterogeneity in terms of size, location, level of care, local management strategies, and resource availability. PMID: 32475305 [PubMed - as supplied by publisher]
Publication date: Available online 1 June 2020Source: Pathology - Research and PracticeAuthor(s): Zhi-Yun Zhang, Meng Lu, Ze-Kun Liu, Hao Li, Yu-Le Yong, Ren-Yu Zhang, Zhi-Nan Chen, Huijie Bian
Authors: Tang B, Qi G, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, Wei Y, Zhai R, Lei B, Yu H, Jiao X, He S Abstract [This corrects the article DOI: 10.18632/oncotarget.3713.]. PMID: 32477467 [PubMed - in process]
Authors: Zamanian-Daryoush M, Lindner DJ, Buffa J, Gopalan B, Na J, Hazen SL, DiDonato JA Abstract Previously, we reported apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), has potent anti-melanoma activity. We used DNA microarray and bioinformatics to interrogate gene expression profiles of tumors from apoA-I expressing (A-I Tg+/-) versus apoA-I-null (A-I KO) animals to gain insights into mechanisms of apoA-I tumor protection. Differential expression analyses of 11 distinct tumors per group with> 1.2-fold cut-off and a false discovery rate adjusted p
Authors: Miranti CK, Moore S, Kim Y, Chappeta VR, Wu K, De B, Gokhale V, Hurley LH, Reyes-Reyes EM Abstract The androgen receptor (AR) is a major driver of prostate cancer development and progression. Men who develop advanced prostate cancer often have long-term cancer control when treated with androgen-deprivation therapies (ADT). Still, their disease inevitably becomes resistant to ADT and progresses to castration-resistant prostate cancer (CRPC). ADT involves potent competitive AR antagonists and androgen synthesis inhibitors. Resistance to these types of treatments emerges, primarily through the maintenance of ...
Conclusions: Evaluation of ctDNA was feasible among individuals with NEN. Liquid biopsies are non-invasive methods that can provide personalized options for targeted therapies in NEN patients. Patients and Methods: Molecular alterations in 338 plasma samples from 320 patients with NEN were evaluated using clinical-grade NGS of ctDNA (Guardant360®) across multiple institutions. The test detects single nucleotide variants in 54-73 genes, copy number amplifications, fusions, and indels in selected genes. PMID: 32477464 [PubMed]
More News: Academia | Academies | Adenocarcinoma | Allergy & Immunology | Avastin | Biotechnology | Bladder Cancer | Bone Cancers | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Chemotherapy | China Health | Clear Cell Carcinoma | Clinical Trials | Colon Cancer | Colorectal Cancer | Endometrial Cancer | Endometrioid Carcinoma | Epidemiology | Epithelial Cancer | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Germany Health | Hepatocellular Carcinoma | Hospitals | Immunotherapy | Japan Health | Kidney Cancer | Laboratory Medicine | Liver Cancer | Lung Cancer | Melanoma | Men | Menopause | Molecular Biology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Netherlands Health | Non-Small Cell Lung Cancer | Nutrition | OBGYN | Oral Cancer | Osteosarcoma | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Perfusion | Prostate Cancer | Renal Cell Carcinoma | Reproduction Medicine | Science | Serous Carcinoma | Skin Cancer | Sodium | Squamous Cell Carcinoma | Statistics | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | Texas University | USA Health | Women